1.6200 +0.04 (2.53%)
After hours: 6:07PM EST
|Bid||1.5800 x 36200|
|Ask||1.5900 x 40000|
|Day's Range||1.5700 - 1.6800|
|52 Week Range||1.3300 - 3.8700|
|Beta (5Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.13|
BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, Inc., and oncology, urology and women’s health division, GenPath Diagnostics, are pleased to provide a 2019 business update, highlighting new tests that lead to faster diagnoses, payer relationships that provide greater access to care, and new tools that empower patients to take responsibility of their health. Work completed by the company this year reinforces its commitment to healthcare providers, patients and payers, as well as the local community and its employees.
OPKO Health, Inc. (OPK) announced today that management will be participating in the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 at the Westin St. Francis in San Francisco. The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here. OPKO Health is a diversified healthcare company.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So...
OPKO Health, Inc. (OPK) today announced that Company management will be participating in the 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the Lotte New York Palace in New York City. Management will be hosting one-on-one meetings with investors and will be presenting in a “Fireside Chat” format on Wednesday, December 4 at 12:30 p.m. Eastern time. The “Fireside Chat” will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here.
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with defined coverage criteria, effective December 30, 2019.
OPKO Health (OPK) delivered earnings and revenue surprises of -22.22% and 1.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
MIAMI, Nov. 05, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2019. Business Highlights.
Elmwood Park, NJ, Nov. 04, 2019 -- BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women’s health.
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MIAMI, Nov. 01, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide.